
Australia's second-biggest biotech company has posted its first-ever profit as its radioactive imaging agent for diagnosing prostate cancer continues to gain market share.
ASX-listed Telix Pharmaceuticals announced on Friday it had made $5.2 million in net profit for the six months to December, compared to a $104 million net loss in the second half of 2022.